Real Human Skin That Lasts Four Weeks

Outer Biosciences, LLC has ended its private operations in August 2026 and publicly introduced its preclinical research platform, Yuna. Yuna maintains the epidermis, dermis, resident cells, and immune-related molecular programs of full-thickness human skin donated post-surgery for over 30 days, significantly extending the observation period compared to conventional ex vivo skin models, which typically last about one week. Its core feature is the ability to repeatedly measure phenomena that develop over several weeks, such as chronic inflammation, UV damage recovery, aging, and collagen and extracellular matrix remodeling, within the same tissue.

Combination of Machine Learning and Proprietary Data

Machine learning (ML) evaluates millions of compounds daily, and Yuna validates predicted candidates in real human skin, feeding the results back into the model for further learning. According to company data, annual computational processing capacity reaches 750 million compounds, with over 10 terabytes of data accumulated from more than 300 donors and 10,000 potential treatment groups. Each compound-sample combination generates over 30,000 data points, enabling faster candidate screening and analysis of skin-type-specific response differences. This structure gives a competitive edge over generic AI models that rely on public data, as the speed of proprietary data accumulation becomes a key differentiator.

Focus on Discovery Platforms Rather Than New Drugs

Yuna is not a drug candidate with a specific brand, generic name, or molecular target, but a preclinical discovery platform, and therefore does not fall under Phase 1, 2, or 3 clinical trials or FDA, EMA, or PMDA approval stages. Rather than developing drugs in-house, Outer provides collaborative research and data services to pharmaceutical, biotech, cosmetic, and ingredient companies, currently collaborating with Haus Labs. Revenue is also generated from pharmaceutical projects studying severe skin rashes caused by cancer treatments, aiming to reduce candidate failures before clinical trials.

Commercialization Backed by $23 Million

The company has raised a cumulative $23 million since its founding, with a current workforce of 19. Investors include Wing Venture Capital, Initialized Capital, Sozo Ventures, and Hawktail, founded by entrepreneur Michael Polish. This amount represents the total cumulative venture investment, not a single license contract's upfront payment or milestone, and does not involve royalties. The asset-light structure, which does not bear direct clinical trial costs, offers high capital efficiency, but recurring revenue and partner conversion rates remain key valuation verification metrics.

Competitive Landscape and Regulatory Tailwinds

Competing alternatives include MatTek (under Sartorius)’s reconstructed epidermis EpiDerm, Emulate’s organ-on-a-chip, and Vivodyne’s lab-cultured human tissues. While Yuna differentiates itself through the long-term survival of real full-thickness skin and diverse donor data, it must compete with standardized models in terms of throughput, reproducibility, and regulatory eligibility. The FDA published a roadmap in April 2025 to reduce animal testing dependency by adopting AI models, organoids, and organ-on-a-chip as New Approach Methodologies (NAMs), reinforcing demand. The 2026 global dermatology drug market is projected at $54.6 billion, growing to $83.9 billion by 2031, representing the targetable market based solely on pharmaceutical clients, with additional opportunities from cosmetic and ingredient research demand.